NCT01768403已完成不适用
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,236
- 主要终点
- Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.
研究概览
简要总结
Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.
详细描述
Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must provide informed consent and comply with the survey procedures.
- •Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
排除标准
- •Subjects who are unwilling or unable to provide informed consent.
结局指标
主要结局
Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.
时间窗: 24 weeks
次要结局
- The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models(24 weeks)
- Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines(24 weeks)
- Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.(24 weeks)
- Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.(24 weeks)
研究者
相似试验
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01604733AstraZeneca1,000
已完成
不适用
Polish Survey on the Efficacy of the Hypercholesterolemia TreatmentHypercholesterolemiaNCT01243255AstraZeneca1,500
已完成
不适用
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemiaNCT01031277AstraZeneca1,000
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
InPractice Survey on the Treatment of HypercholesterolemiaHypercholesterolemiaNCT00523796AstraZeneca2,500